Sugi Predict

Sugi Predict / Compounds / SCHEMBL1777800

SCHEMBL1777800

SCHEMBL1777800

CCCOC(=O)C(=O)ONN

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ GAA P10253 1/20 0.39
▸ HCAR2 Q8TDS4 1/20 0.36
▸ ALDH1A1 P00352 4/20 0.35
▸ MAPK1 P28482 2/20 0.35
▸ TSHR P16473 3/20 0.34
▸ LMNA P02545 2/20 0.34
▸ ESR1 P03372 1/20 0.33
▸ CHRM1 P11229 1/20 0.33
▸ SLC6A2 P23975 1/20 0.33
▸ KDR P35968 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ CTSD P07339 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ GLA P06280 1/20 0.33
▸ ACHE P22303 1/20 0.32
▸ EPHX1 P07099 1/20 0.31
▸ THRB P10828 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1234311 0.88 ALDH1A1 (0.48) HCAR2ALDH1A1TSHRLMNATDP1
SCHEMBL289464 0.82 GAA (0.44) SMN1; SMN2GAAALDH1A1TSHRLMNA
SCHEMBL16279760 0.81 TSHR (0.37) SMN1; SMN2GAAALDH1A1TSHRKDM4E
SCHEMBL138475 0.81 HCAR2 (0.48) SMN1; SMN2GAAHCAR2ALDH1A1TSHR
SCHEMBL7364406 0.80 — —
Water SCHEMBL27557216 0.78 HCAR2 (0.46) SMN1; SMN2GAAHCAR2ALDH1A1TSHR
SCHEMBL2977390 0.77 GAA (0.43) SMN1; SMN2GAAHCAR2ALDH1A1MAPK1
SCHEMBL28249509 0.76 SMN1; SMN2 (0.47) SMN1; SMN2GAAHCAR2ALDH1A1MAPK1
SCHEMBL1144851 0.75 CYP1A2 (0.35) TSHRLMNA
SCHEMBL1977993 0.74 ALDH1A1 (0.48) SMN1; SMN2GAAHCAR2ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108746656-B Pre-alloyed powder for diamond products and preparation method thereof 威海职业学院 2021-11-26 — — CN claimed
US-7943636-B2 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-05-17 — — US disclosed
CN-101084217-B Imidazo [4,5-B] pyridin-2-ones and oxazolido [4,5-B] pyridin-2-ones and analogues thereof as therapeutic compounds CANCER REC TECH LTD 2010-10-13 — — CN disclosed
EP-2197875-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS Via Pharmaceuticals, Inc. (US) 2010-06-23 — — EP disclosed
US-20090163533-A1 1-Substituted Pyrazolo (3,4-C) Ring Compounds as Modulators of Cytokine Biosynthesis for the Treatment of Viral Infections and Neoplastic Diseases COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-06-25 — — US disclosed
WO-2009037222-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS VIA PHARMACEUTICALS, INC. (US) 2009-03-26 — — WO disclosed
US-20090076275-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS VIA PHARMACEUTICALS, INC. 2009-03-19 — — US disclosed
EP-1863814-A1 1-SUBSTITUTED PYRAZOLO (3,4-C) RING COMPOUNDS AS MODULATORS OF CYTOKINE BIOSYNTHESIS FOR THE TREATMENT OF VIRAL INFECTIONS AND NEOPLASTIC DISEASES Coley Pharmaceutical Group, Inc. (US) 2007-12-12 — — EP disclosed
CN-101084217-A Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds CANCER REC TECH LTD (GB) 2007-12-05 — — CN disclosed
CN-1330647-C Heterobicyclic substituted phenyl * oxazolidinone antibacterial agents ORTHO MCNELL PHARMACEUTICAL IN (US) 2007-08-08 — — CN disclosed
CN-1414964-A heterobicyclic substituted phenyl oxazolidinone antibacterial agents ORTHO MCNELL PHARMACEUTICAL IN (US) 2003-04-30 — — CN disclosed
US-6407114-B1 BENIGN PROSTATIC HYPERPLASIA, CARDIOVASCULAR, GASTROINTESTINAL AND RESPIRATORY DISORDER TREATMENT; ANTIASTHMATIC, ANTIALLERGEN, AND ANTIDIABETIC AGENTS PFIZER INC. 2002-06-18 — — US disclosed
EP-1171122-A4 PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO INC (US) 2002-05-29 — — EP disclosed
EP-1171122-A1 PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Merck & Co., Inc. (US) 2002-01-16 — — EP disclosed
US-6248755-B1 ANTIINFLAMMATORY AGENTS; ANTIALLERGENS; AUTOIMMUNE DISEASES MERCK & CO., INC. 2001-06-19 — — US disclosed
WO-2000059502-A1 PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO., INC. (US) 2000-10-12 — — WO disclosed
EP-0995751-A2 Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction PFIZER INC. (US) 2000-04-26 — — EP disclosed
US-4075222-A VETERINARY MEDICINE, BACTERICIDES, FUNGICIDES, ANTIPROTOZOAN ELI LILLY AND COMPANY (US) 1978-02-21 — — US disclosed
US-3980794-A Method for promoting growth of poultry with 3-(5-nitro-2-imidazolyl)pyrazoles ELI LILLY AND COMPANY (US) 1976-09-14 — — US disclosed
US-3947467-A ANTIBACTERIAL, ANTIPROTOZOAL, ANTIFUNGAL ELI LILLY AND COMPANY (US) 1976-03-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076275-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS DGAT2, DGAT1, LCAT SMN1; SMN2 4066/4885GAA 200/4885HCAR2 2111/4885
US-20090163533-A1 1-Substituted Pyrazolo (3,4-C) Ring Compounds as Modulators of Cytokine Biosynthesis for the Treatment of Viral Infections and Neoplastic Diseases IL2, IL4, IFNG SMN1; SMN2 4525/4885GAA 2310/4885HCAR2 2145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.